Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Synopsys, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The investigation is focused on whether Synopsys has engaged in any unlawful activities that may have affected its stockholders [2]. - Investors who have suffered losses and are interested in discussing their legal rights are encouraged to contact the law firm [3]. Company Performance - On September 9, 2025, Synopsys reported its financial results for Q3 2025, indicating that its IP business underperformed expectations [6]. - The CEO of Synopsys expressed a more conservative outlook for Q4 while guiding for another year of profitable growth [6]. - Following the announcement, Baird downgraded Synopsys's rating from Outperform to Neutral and reduced its price target from $670 to $535 [6]. - As a result of this news, Synopsys's stock price dropped by $216.59, or 35.84%, closing at $387.78 per share on September 10, 2025 [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics for possible violations of federal securities laws and unlawful business practices, following a significant drop in the company's stock price after a trial report [1][2]. Investigation Details - The investigation focuses on whether MoonLake has engaged in unlawful business practices that may have led to investor losses [1][2]. - The firm is encouraging investors who suffered losses to contact them for discussions regarding their legal rights [1][3]. Stock Performance - On September 29, 2025, MoonLake Immunotherapeutics reported that its VELA-2 trial did not achieve statistical significance due to unexpected results in the placebo group, leading to a drastic stock decline of 89.9% on the same day [6].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly making materially false and misleading statements regarding its product Pylarify and its competitive position during the specified class period [3][7]. Allegation Details - The lawsuit claims that Lantheus provided overly positive statements while concealing adverse facts about Pylarify's competitive position [3]. - It is alleged that Lantheus was not adequately equipped to assess pricing and competitive dynamics for Pylarify [3]. - The company reportedly failed to disclose that a price increase in early 2025, despite previous price erosion, created opportunities for competitive pricing, jeopardizing Pylarify's price point and growth potential [3]. - As a result, the statements made by the defendants regarding the company's business and prospects were materially false and misleading [3]. Next Steps - Investors who purchased Lantheus shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4]. - There is no cost or obligation for investors to inquire about their claims [4]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina [5].

Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against Firefly Aerospace Inc. for possible violations of federal securities laws and unlawful business practices [1][2] Company Financials - Firefly conducted an initial public offering of 19.3 million shares at $45.00 per share on August 7, 2025 [6] - For Q2 2025, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, in the same quarter the previous year [6] - Revenue for Q2 2025 was $15.55 million, which was below analyst estimates of $17.25 million and represented a 26.2% decline from the same quarter last year [6] - Following the financial results announcement, Firefly's stock price dropped by $7.58 per share, or 15.31%, closing at $41.94 per share on September 23, 2025 [6]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Inspire Medical Systems, Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - The investigation is focused on whether Inspire has engaged in unlawful business practices that may have led to losses for its stockholders [1][2]. - Investors who have suffered losses and are interested in discussing their legal rights are encouraged to contact the law firm [3]. Company Performance - On August 5, 2025, Inspire announced better-than-expected second quarter fiscal 2025 results but significantly reduced its full-year guidance from earnings of $2.20 - $2.30 on revenue of $940 million - $955 million to earnings of $0.40 - $0.50 on revenue of $900 million - $910 million [6]. - This revision followed a previous increase in earnings guidance just one quarter prior, indicating a sudden downturn in expectations [6]. - Management attributed the guidance cut to slowdowns in the rollout of Inspire V, citing issues such as incomplete training and onboarding, customer delays, technical Medicare adoption delays, and ongoing high demand for Inspire IV devices [6]. - Following this announcement, Inspire's stock price dropped by $46.44 to open at $83.51 per share [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Firefly Aerospace Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether Firefly has engaged in unlawful activities that may have led to financial losses for its investors [1][2]. - Investors who have suffered losses and are interested in discussing their legal rights are encouraged to contact the law firm [3]. Financial Performance - Firefly conducted an initial public offering on August 7, 2025, selling 19.3 million shares at $45.00 each [6]. - For Q2 2025, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, in the same quarter the previous year [6]. - The company's revenue for Q2 2025 was $15.55 million, which was below analyst expectations of $17.25 million and represented a 26.2% decline from the same quarter last year [6]. - Following the financial report, Firefly's stock price dropped by $7.58, or 15.31%, closing at $41.94 per share on September 23, 2025 [6].

Core Points - A class action lawsuit has been filed against PubMatic, Inc. for allegedly making materially false and misleading statements during the Class Period from February 27, 2025, to August 11, 2025 [2][7] - Investors have until October 20, 2025, to apply to be appointed as lead plaintiff in the lawsuit [2] Allegation Details - The lawsuit claims that PubMatic failed to disclose significant adverse facts, including a top DSP buyer shifting clients to a new platform, leading to reduced ad spend and revenue [7] - The company's positive statements regarding its business operations were allegedly misleading due to these undisclosed issues [7] Financial Impact - Following the release of its second quarter 2025 financial report on August 11, 2025, which revealed a reduction in ad spend from a top DSP partner, PubMatic's stock price fell by $2.23, or 21.1%, closing at $8.34 per share on August 12, 2025 [7]

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Albany International Corporation for possible violations of federal securities laws and unlawful business practices [1][2]. Financial Performance - Albany reported non-GAAP earnings per share of $0.57 for Q2 2025, missing consensus estimates by $0.16 [2]. - Following the earnings report, Albany's stock price dropped by $16.77, or 23.63%, closing at $54.19 on July 31, 2025 [2]. Legal Actions - Investors who suffered losses from purchasing Albany shares are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights [1][3]. - The law firm offers no-cost consultations for affected investors [3]. Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with expertise in representing individual and institutional investors in complex litigation [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Semler Scientific Inc. for possible violations of federal securities laws and unlawful business practices [1][2]. Investigation Details - Semler disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 regarding reimbursement claims for its QuantaFlo device [2]. - The company has faced multiple requests for information from the DOJ over the years, with significant discussions occurring in February 2025 that did not lead to a settlement [2]. - Following the disclosure of potential legal risks, Semler's stock price fell from $42.92 to $38.89, a decline of $4.03 per share [2]. Next Steps - Investors who purchased Semler shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims [3]. About the Law Firm - Bragar Eagel & Squire, P.C. is a law firm recognized for representing investors in various complex litigations across state and federal courts [4].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly misleading investors about its revenue outlook and growth projections during the specified class period from December 12, 2024, to June 30, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Centene securities during the class period [1]. - Investors have until September 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Centene - The complaint alleges that Centene created a false impression of having reliable information regarding its projected revenue and growth, while actual enrollment rates and morbidity were lower than expected [3]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than anticipated, leading to a reduction in guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75 [4]. Group 3: Stock Impact - Following the announcement of the revised guidance, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $44.78 per share on July 2, 2025, marking a decline of over 40% [4].